🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in South Korea / NCT07271927
Recruiting Not applicable

Whole-Body Photobiomodulation for Motor and Cognitive Changes in Parkinson's Disease

NCT07271927 · tracked via the Priya Life Science South Korea tracker
Phase
Not applicable
Started
2025-02-12
Last updated
2025-12-09

Condition(s) studied

PARKINSON DISEASE (Disorder)

Investigational drug(s) / intervention(s)

Photobiomodulation

Photobiomodulation: Participants received whole-body PBM therapy over approximately 10 weeks (three sessions per week, once daily, 20 minutes per session), with each session using a randomly selected wavelength of either 660 nm, 850 nm, or 940 nm (±20%).

Study summary

This study aims to exploratorily evaluate the extent of motor and cognitive changes, as well as the safety, resulting from approximately 10 weeks of whole-body photobiomodulation (PBM) therapy (about three sessions per week, once daily, 20 minutes per session) in patients with Parkinson's disease.

Eligibility

Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Individuals diagnosed with Parkinson's disease at Hoehn and Yahr stages 1-3 based on medical history and examination * Adults aged 40 years or older * Individuals able to walk independently Exclusion Criteria: * Individuals with severe cognitive impairment (Korean Mini-Mental State Examination \[K-MMSE\] score ≤ 9) making it difficult to understand and perform tasks * Patients with dementia other than Parkinson's disease dementia * Individuals with implanted medical or other electronic devices * Individuals with severe neuropsychiatric disorders * Individuals treated for alcohol dependence within 6 months prior to screening * Individuals with a history of suicide attempts * Individuals with a history of seizures * Individuals experiencing dyspnea while sitting at rest * Individuals with visual impairment preventing them from reading ordinary text even with corrective lenses * Individuals with hearing impairment preventing them from understanding conversation even with a hearing aid * Individuals who have participated in two or more clinical trials in the same year or in another clinical trial within the past 6 months * Women and men of childbearing potential who are planning pregnancy during the trial or who do not agree to use appropriate contraceptive methods * Pregnant or breastfeeding women * Individuals deemed medically inappropriate for participation by the principal investigator or study staff based on clinically significant findings not otherwise specified above

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Pusan National University Yangsan Hospital Yangsan Gyeongsangnam-do Recruiting

More Pusan National University Yangsan Hospital trials in South Korea

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07271927 on ClinicalTrials.gov ↗ ← All trials in South Korea